Saturday, July 11, 2026

pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN

Regeneron UK

Regeneron UK is a pharma organization headquartered in Tarrytown, USA. It trades on NYSE under ticker REGN. Primary therapeutic focus areas include Diabetic Macular Edema, Hypercholesterolemia, Asthma, Macular Degenerati

Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
Clinical program

REGN2810

Phase 1 · small molecule · Recurrent Squamous Cell Carcinoma of Head

REGN2810 for Recurrent Squamous Cell Carcinoma of Head is a Phase 1 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

← All Regeneron UK Limited projects Phase 1 small molecule completed

Internal code R2810-ONC-1655

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Regeneron UK Limited
Phase
Phase 1
Modality
small_molecule
Indication
Recurrent Squamous Cell Carcinoma of Head
Status
completed
Trials
1

Clinical trials